Brief: vTv Therapeutics Says On July 17, Co Received Nasdaq Notice Approving Request To Extend Period To Regain Compliance With Min Bid Requirement Until Dec 18
Brief: vTv Therapeutics Says Nasdaq Indicated It Will Suspend Trading In Co’s Common Stock On June 30 Due To Failure To Satisfy Continued Listing Rule
Brief: vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights To Intellectual Property From Georgetown University
U.S. STOCKS ON THE MOVE-Nvidia, GeoVax Labs, Freshpet
U.S. STOCKS ON THE MOVE-Citigroup, Tigo Energy, Children's Place
vTv Therapeutics rises on patent for brain tumor treatment
Brief: vTv Therapeutics Announces Issuance Of U.S. Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Brief: Vtv Therapeutics Announces 2023 First Quarter Financial Results And Provides Corporate Update
vTv Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
vTv Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Advisory: Alert on clinical study wrongly tagged to Cantex Mine Development withdrawn
Brief: Cantex Pharmaceuticals Initiation Of Phase 2/3 Study To Determine Safety, Efficacy Of Azeliragon In Treatment Of Patients Hospitalized For Covid-19
Brief: vTv Therapeutics Announces Q4 Results
Brief: vTv Therapeutics Announces Q4 Results
Brief: Cantex Receives FDA "Study May Proceed" Letter For Phase 2 Clinical Trial Of Unmethylated Glioblastoma Deug Azeliragon
Brief: Elizabeth Keiley Selected As Executive Vice President And General Counsel Of vtv Therapeutics
Brief: vTv Therapeutics Receives Notice Of Delisting From Nasdaq
Brief: vTv Therapeutics Appoints Steven Tuch As CFO
vTv Therapeutics Inc reports results for the quarter ended in September - Earnings Summary